Hongyang Shu

853 total citations
23 papers, 528 citations indexed

About

Hongyang Shu is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Hongyang Shu has authored 23 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 8 papers in Molecular Biology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Hongyang Shu's work include Cardiovascular Function and Risk Factors (5 papers), Cardiac Ischemia and Reperfusion (4 papers) and Cardiac Imaging and Diagnostics (3 papers). Hongyang Shu is often cited by papers focused on Cardiovascular Function and Risk Factors (5 papers), Cardiac Ischemia and Reperfusion (4 papers) and Cardiac Imaging and Diagnostics (3 papers). Hongyang Shu collaborates with scholars based in China, United States and Germany. Hongyang Shu's co-authors include Dao Wen Wang, Ning Zhou, Weijian Hang, Yizhong Peng, Jiali Nie, Na Li, Zixuan Zhang, Shuo Tian, Wen Zheng and Xiangcheng Qing and has published in prestigious journals such as SHILAP Revista de lepidopterología, Free Radical Biology and Medicine and Small.

In The Last Decade

Hongyang Shu

20 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hongyang Shu China 13 222 174 85 72 66 23 528
Xiuhong Yang China 14 172 0.8× 120 0.7× 63 0.7× 46 0.6× 62 0.9× 45 620
Yun Ti China 14 202 0.9× 199 1.1× 115 1.4× 30 0.4× 92 1.4× 45 564
Wanting Shi China 11 263 1.2× 120 0.7× 80 0.9× 51 0.7× 72 1.1× 30 555
Justyna Totoń‐Żurańska Poland 15 210 0.9× 154 0.9× 97 1.1× 28 0.4× 99 1.5× 37 537
Abdolrahim Nikzamir Iran 15 141 0.6× 152 0.9× 67 0.8× 82 1.1× 110 1.7× 54 639
Tingbo Jiang China 13 259 1.2× 199 1.1× 128 1.5× 109 1.5× 45 0.7× 61 698
Ruijuan Wang China 14 293 1.3× 101 0.6× 112 1.3× 87 1.2× 59 0.9× 43 694
Eman Salah Egypt 15 196 0.9× 79 0.5× 63 0.7× 43 0.6× 38 0.6× 33 679

Countries citing papers authored by Hongyang Shu

Since Specialization
Citations

This map shows the geographic impact of Hongyang Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongyang Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongyang Shu more than expected).

Fields of papers citing papers by Hongyang Shu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongyang Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongyang Shu. The network helps show where Hongyang Shu may publish in the future.

Co-authorship network of co-authors of Hongyang Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Hongyang Shu. A scholar is included among the top collaborators of Hongyang Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongyang Shu. Hongyang Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shu, Hongyang, Chen Chen, Luyun Wang, Jiangang Jiang, & Dao Wen Wang. (2024). Brief Version of Chinese Society of Cardiology Guidelines on the Diagnosis and Treatment of Adult Fulminant Myocarditis. 100012–100012.
2.
Shu, Hongyang, Wen Zheng, Na Li, et al.. (2023). COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations. Aging and Disease. 14(6). 2071–2071. 14 indexed citations
3.
Shu, Hongyang, Jia Cheng, Na Li, et al.. (2023). Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance. Cardiovascular Diabetology. 22(1). 192–192. 37 indexed citations
4.
Nie, Jiali, Yu Han, Weijian Hang, et al.. (2023). Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy. Gene Therapy. 30(6). 520–527. 16 indexed citations
5.
Peng, Yizhong, Xuanzuo Chen, Sheng Liu, et al.. (2023). Extracellular Vesicle‐Conjugated Functional Matrix Hydrogels Prevent Senescence by Exosomal miR‐3594‐5p‐Targeted HIPK2/p53 Pathway for Disc Regeneration. Small. 19(37). e2206888–e2206888. 32 indexed citations
6.
7.
Zhang, Min, et al.. (2022). Epoxyeicosatrienoic acid: A potential therapeutic target of heart failure with preserved ejection fraction. Biomedicine & Pharmacotherapy. 153. 113326–113326. 8 indexed citations
8.
Shu, Hongyang, Yizhong Peng, Weijian Hang, et al.. (2022). Emerging Roles of Ceramide in Cardiovascular Diseases. Aging and Disease. 13(1). 232–232. 42 indexed citations
9.
Li, Na, Weijian Hang, Hongyang Shu, & Ning Zhou. (2022). RBM20, a Therapeutic Target to Alleviate Myocardial Stiffness via Titin Isoforms Switching in HFpEF. Frontiers in Cardiovascular Medicine. 9. 928244–928244. 6 indexed citations
10.
Shu, Hongyang, Weijian Hang, Min Zhang, et al.. (2022). Trimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoter. Acta Pharmacologica Sinica. 43(10). 2550–2561. 10 indexed citations
11.
Li, Na, et al.. (2022). Salvianolic Acid Ameliorates Pressure Overload-Induced Cardiac Endothelial Dysfunction via Activating HIF1α/HSF1/CD31 Pathway. The American Journal of Chinese Medicine. 50(7). 1869–1885. 4 indexed citations
12.
Li, Na, Weijian Hang, Hongyang Shu, & Ning Zhou. (2022). Pirfenidone alleviates cardiac fibrosis induced by pressure overload via inhibiting TGF‐β1/Smad3 signalling pathway. Journal of Cellular and Molecular Medicine. 26(16). 4548–4555. 26 indexed citations
13.
Shen, Lan, Lin Qiu, Jingbo Liu, et al.. (2021). Clinical Implications of Nicorandil Combined with Trimetazidine in Patients with Coronary Heart Disease: A Real-World Observational Study. Advances in Therapy. 39(1). 655–673. 6 indexed citations
14.
Hang, Weijian, Hongyang Shu, Wen Zheng, et al.. (2021). N-Acetyl Cysteine Ameliorates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease and Intracellular Triglyceride Accumulation by Preserving Mitochondrial Function. Frontiers in Pharmacology. 12. 636204–636204. 20 indexed citations
15.
Shu, Hongyang, Yizhong Peng, Weijian Hang, Ning Zhou, & Dao Wen Wang. (2021). Trimetazidine in Heart Failure. Frontiers in Pharmacology. 11. 569132–569132. 46 indexed citations
16.
Shu, Hongyang, Weijian Hang, Jiali Nie, et al.. (2021). Trimetazidine Attenuates Heart Failure by Improving Myocardial Metabolism via AMPK. Frontiers in Pharmacology. 12. 707399–707399. 26 indexed citations
17.
Shu, Hongyang, Yizhong Peng, Weijian Hang, Ning Zhou, & Dao Wen Wang. (2021). Emerging role of VCP/p97 in cardiovascular diseases: novel insights and therapeutic opportunities. Biochemical Society Transactions. 49(1). 485–494. 8 indexed citations
18.
Peng, Yizhong, Shuo Tian, Sheng Liu, et al.. (2021). Glucagon-like peptide-1 receptor activation maintains extracellular matrix integrity by inhibiting the activity of mitogen-activated protein kinases and activator protein-1. Free Radical Biology and Medicine. 177. 247–259. 13 indexed citations
19.
Shu, Hongyang, Yizhong Peng, Weijian Hang, et al.. (2020). The role of CD36 in cardiovascular disease. Cardiovascular Research. 118(1). 115–129. 155 indexed citations
20.
Fan, Jingjing, Lin Qiu, Hongyang Shu, et al.. (2017). Recombinant frizzled1 protein attenuated cardiac hypertrophy after myocardial infarction via the canonical Wnt signaling pathway. Oncotarget. 9(3). 3069–3080. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiuhong Yang Breakdown of academic impact, for papers by Yun Ti Breakdown of academic impact, for papers by Wanting Shi Breakdown of academic impact, for papers by Justyna Totoń‐Żurańska Breakdown of academic impact, for papers by Abdolrahim Nikzamir Breakdown of academic impact, for papers by Tingbo Jiang Breakdown of academic impact, for papers by Ruijuan Wang Breakdown of academic impact, for papers by Eman Salah
Rankless by CCL
2026